Business Wire

Calvin Klein, Inc. Announces Multi-Year Collaboration with The Andy Warhol Foundation for the Visual Arts

Del

Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. (NYSE:PVH), today announced a multi-year partnership with The Andy Warhol Foundation for the Visual Arts, Inc.

Calvin Klein, Inc.’s financial commitment will support the foundation’s endowment from which it distributes grants sustaining the creation, presentation and documentation of contemporary visual art. In turn, Calvin Klein will be granted unprecedented access to the late artist’s works, including many that have not yet been published. The global partnership is effective through 2020 and will extend to licensing projects across various business lines and future activations within the CALVIN KLEIN brand portfolio.

“I am proud that through this licensing agreement with The Andy Warhol Foundation for the Visual Arts, Calvin Klein will be continuing its longstanding commitment to the celebration of American artists and their prolific work,” said Steve Shiffman, Chief Executive Officer, Calvin Klein, Inc. “I look forward to the global rollout of this partnership across multiple levels of the CALVIN KLEIN consumer experience.”

“I’ve come to realize that Warhol’s genius goes much deeper than cheerful Campbell’s Soup paintings,” said Raf Simons, Chief Creative Officer. “He captured all sides of the American experience, including sometimes its darker sides. Warhol’s art tells more truths about this country than you can find almost anywhere else.”

“Warhol’s legacy is not limited to the tremendous influence of his timeless concepts but also through the work of the foundation he established, which has become one of the pre-eminent funders of contemporary art having distributed over $275 million in grants since inception,” said Michael Dayton Hermann, Director of Licensing at the Warhol Foundation. “We are proud that Raf’s visionary work at Calvin Klein will unabashedly embrace all facets of Warhol’s work and generously contribute to the foundation’s endowment.”

The first iteration of the partnership was unveiled in September 2017, with Raf Simons’ Spring 2018 CALVIN KLEIN 205W39NYC runway show. The collection, which is available in stores in January 2018, incorporates a selection of Warhol artworks as placement screen prints. The body of work is intimately connected to the collection’s inspirations of cinema, the dream factory of Hollywood and its depictions of both an American nightmare and the all-powerful American dream. The pieces feature portraits of Warhol intimate and art collector Sandra Brant (1971) and movie star Dennis Hopper (1971), as well as Knives (1981–82), Electric Chair (1964–65), and Ambulance Disaster (1963–64) from Warhol’s Death and Disaster series. The collection also features pieces produced under license and in collaboration with Hopper Goods, a brand inspired by the life and spirit of actor, photographer, and iconoclast Dennis Hopper.

Andy Warhol’s links to fashion dated back to his first years as an artist, when his witty shoe pictures drew eyes to Vogue and Harper’s Bazaar. In the 1970s, the connection became more personal when Warhol befriended a fresh generation of New York designers that of course included Mr. Calvin Klein himself. Klein had set out to capture a new, truly American essence in his creations, and that meshed perfectly with Warhol’s own interests.

Now, 30 years after Warhol’s death, Simons is setting out to renew the relationship between the great American fashion house of CALVIN KLEIN and this greatest of American artists. Thanks to The Andy Warhol Foundation for the Visual Arts, Simons has been forging what he sees as a deep, thoroughgoing collaboration with the undying genius of Warhol, built on the creative ideals that they share. Like Warhol’s art, Simons’ designs for 2018 and beyond are committed to a fearless embrace of the place and the times that we live in.

About Calvin Klein

CALVIN KLEIN is a global lifestyle brand that exemplifies bold, progressive ideals and a seductive aesthetic. We seek to thrill and inspire our audience while using provocative imagery and striking designs to ignite the senses.

Founded in 1968 by Calvin Klein and his business partner Barry Schwartz, we have built our reputation as a leader in American fashion through our clean aesthetic and innovative designs. Global retail sales of CALVIN KLEIN brand products exceeded $8 billion in 2016 and were distributed in over 110 countries. CALVIN KLEIN employs over 10,000 associates globally. We were acquired by PVH Corp. in 2003.

About PVH Corp.

With a history going back over 135 years, PVH has excelled at growing brands and businesses with rich American heritages, becoming one of the largest apparel companies in the world. We have over 35,000 associates operating in over 40 countries and over $8 billion in annual revenues. We own the iconic CALVIN KLEIN , TOMMY HILFIGER , Van Heusen , IZOD , ARROW , Speedo *, Warner’s and Olga brands, as well as the digital-centric True & Co. intimates brand, and market a variety of goods under these and other nationally and internationally known owned and licensed brands.

*The Speedo brand is licensed for North America and the Caribbean in perpetuity from Speedo International Limited.

About The Andy Warhol Foundation for the Visual Arts, Inc.

As the preeminent American artist of the 20th Century, Andy Warhol challenged the world to see art differently. Since its founding in 1987 in accordance with Andy Warhol’s will, The Andy Warhol Foundation has established itself as among the leading funders of contemporary art in the United States having distributed over $275,000,000 in grants supporting the creation, presentation and documentation of contemporary visual arts, particularly work that is experimental, under-recognized or challenging in nature. The foundation’s ongoing efforts to protect and enhance its founder’s creative legacy ensure that Warhol’s inventive, open-minded spirit will have a profound impact on the visual arts for generations to come. Proceeds the foundation receives from licensing projects such as this contribute to the Foundation’s endowment from which it distributes grants. For more information please visit www.warholfoundation.org.

EDITORIAL CREDIT:

 

CALVIN KLEIN

 

SOCIAL MEDIA:

facebook.com/calvinklein ; calvinklein.tumblr.com ; google.com/+calvinklein ;

youtube.com/calvinklein ; twitter.com/calvinklein ; instagram.com/calvinklein ;

pinterest.com/calvinklein

snapchat: calvinklein

 

brand handle: @calvinklein

Contact information

Calvin Klein, Inc.
Alexandra Wagner, 212-292-9794
SVP, Corporate Communications
alexandrawagner@ck.com
or
Amanda Peña, 212-292-9223
Director, Corporate Communications
amandapena@ck.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 02:53Pressemelding

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and

CES Asia: Innovation at the Speed of 5G15.6.2018 14:59Pressemelding

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

AGP Group Announces the Acquisition of Soliver NV in Belgium, Representing a Key Step towards Becoming the Premier Global Leader in Designing and Manufacturing High-Tech Automotive Glazing15.6.2018 09:00Pressemelding

AGP, a high-tech specialty glass designer and manufacturer, has announced today the acquisition of Soliver NV, a European automotive glazing manufacturer with over 65 years of solid product and brand reputation. Soliver offers high-quality tempered and laminated glazing for high-end automobiles, as well as windshield solutions for trucks. AGP’s glazing heritage started in Berlin, with the Mannheim family´s first glass company. After 100 years and a clear vision to become a leader in specialty glass, AGP’s core eGlass technologies have responded to the rising demand in electrification, connectivity, shared mobility and autonomous driving, acting as an enabler of future mobility trends. The integration of Soliver into the AGP Group will strengthen the AGP eGlass value proposition and will be a game changer in a fast-evolving industry. “We are very excited to build upon Soliver’s great experience and track-record to take high-tech glazing to the next level, enabling our customer’s product

Rivoli Group announces completion of its new international corporate strategy15.6.2018 07:00Pressemelding

Rivoli Group AG completes its comprehensive operational restructuring process and acts with a new presence in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180615005085/en/ Rivoli Group Announces Completion of Its New International Corporate Strategy (Photo: Business Wire) The Swiss based Rivoli Group AG has now completed the comprehensive restructuring process as part of the international realignment of its corporate strategy. After an intensive evaluation of the situation, the available resources and existing market potential, the Chairman of the Board of Directors Mr. Mourad Malloul, the management team and an international advisory committee coordinated the strategy together. "This is the beginning of a crucial new chapter for the Rivoli Group," the President and CEO of Rivoli Group AG said. The measure aims to strengthen the competitive advantages within the company group, to adjust their service offerings